[Pressure reducing effect of bupranolol and pilo eserine in chronic glaucoma with open iridocorneal angle].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to I Oancea.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
In two previous studies the effects of topically applied 1% and 0.2% solutions of bupranolol on intraocular pressure were investigated in 21 and respectively 20 eyes with chronic uncomplicated open-angle glaucoma.--As early as 30 minutes after both solutions a very significant pressure drop, without concomittant pupillary reaction, was recorded. The 1% bupranolol solution was less well tolerated and caused some ocular irritation. The present study was therefore initiated in order to find out whether a 0.2% solution of bupranolol would yield significantly different results in comparison with the former.--Statistical evaluation, based on variance analysis linked with multiple t-tests, showed a barely significant difference between the pressure-lowering effects of the 1% and 0.2% solutions after one hour, whereas after 2 hours the difference became clearly significant in favour of the 0.2% solution. Furthermore, the 0.2% solution clearly showed a tendency to prolonged duration of effect, beyond the two-hour observation time. It therefore seems justified to supplement the present findings by long-term studies aimed at assessing optimal concentrations of the drug on the one hand, and its long-acting properties on the other. In this way, bupranolol is likely to gain recognition as an antiglaucomatous agent.
Explore the source record for details and available documents.
In 27 patients with non-compensated or medically compensated chronic simple glaucoma, the I.O.P. was measured after the administration of two tablets of beta-isoket (which contain 5 mg isosorbiddinitrate and 40 mg bupranolol). In none of the 54 eyes was the I.O.P. higher after administration of the drug. On the contrary, the I.O.P. was siginificantly or highly significantly reduced for more than 2 hours, probably because of the beta-receptor-blocking component of the preparation.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Determinations for decelerating the antitoxoplasma anticorps that have been effectuated for 696 uveas proved positivity at 123 aerums (17.6%). The repartition of the positive serology concerning the clinic form of the uvea has proved 48 iridocyclitis, 26 serous central corioretinals, 23 in panuveitis, 13 in posterior uveitis, 11 muscular chorioretinitis, 2 in hyalitis. Taking into consideration only the equal or less than 1:160 titrures, these have been at 7 iridocyclitis, 4 serous central chorioretinitis, 4 panuveitis, 3 posterior uveitis and 3 atrophic central chorioretinitis. It is shown that the diagnosis of ocular toxoplasma must be effectuated just corroborating the clinic data with the positive serology. The antiparasitic treatment doesn't influence upon the low titrures of serous anticorps, which generally maintain at the same value all the life.
The study was carried out on a group of 127 patients, admitted into the Cluj-Napoca Clinic of Ophthalmology, suspected of primary glaucoma with open angle. The complex antiglaucomatous investigation confirmed the diagnosis in 57 cases.
The action of phyroxicam was studied in the treatment of inflammatory affections of the eye globe. Pyroxicam proved to be an efficient nonsteroid anti-inflammatory drug in the treatment of iridocyclitis, keratoiridocyclitis, uveitis etc.
Explore the source record for details and available documents.
Explore the source record for details and available documents.